Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

554 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Parving HH, et al. Among authors: Arner P. N Engl J Med. 2001 Sep 20;345(12):870-8. doi: 10.1056/NEJMoa011489. N Engl J Med. 2001. PMID: 11565519 Clinical Trial.
Ten of the 194 patients in the 300-mg group (5.2 percent) and 19 of the 195 patients in the 150-mg group (9.7 percent) reached the primary end point, as compared with 30 of the 201 patients in the placebo group (14.9 percent) (hazard ratios, 0.30 [95 percent confidence interval, 0.14 to 0.61; P< 0.001] and 0.61 [95 percent confidence interval, 0.34 to 1.08; P=0.081 for the two irbesartan groups, respectively). ...Serious adverse events were less frequent among the patients treated with irbesartan (P=0.02). CONCLUSIONS: Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria....
Ten of the 194 patients in the 300-mg group (5.2 percent) and 19 of the 195 patients in the 150-mg group (9.7 percent) reached the primary e …
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P. Parving HH, et al. Among authors: Arner P. Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Ugeskr Laeger. 2001. PMID: 11601118 Clinical Trial. Danish.
Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p < 0.001 and 0.61 [95 per cent confidence interval 0.34 to 1.08] p = 0.08), respectively). The average blood pressure throughout the study was 144/83, 143/83, and 141/81 mmHg in the placebo, irbesartan 150 mg and 300 mg group, respectively (p = 0.004 for systolic blood pressure). ...
Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary …
Effect of the interaction between diet composition and the PPM1K genetic variant on insulin resistance and β cell function markers during weight loss: results from the Nutrient Gene Interactions in Human Obesity: implications for dietary guidelines (NUGENOB) randomized trial.
Goni L, Qi L, Cuervo M, Milagro FI, Saris WH, MacDonald IA, Langin D, Astrup A, Arner P, Oppert JM, Svendstrup M, Blaak EE, Sørensen TI, Hansen T, Martínez JA. Goni L, et al. Among authors: Arner P. Am J Clin Nutr. 2017 Sep;106(3):902-908. doi: 10.3945/ajcn.117.156281. Epub 2017 Aug 2. Am J Clin Nutr. 2017. PMID: 28768654 Clinical Trial.
In response to the high-fat diet, the T allele was associated with a higher reduction of insulin (β ± SE: -0.77 ± 0.40 μU/mL; P = 0.04) and HOMA-B (β ± SE: -13.2 ± 3.81; P = 0.003). An opposite effect was observed in the low-fat diet group, although in this group the T allele was marginally (P = 0.10) and not significantly (P = 0.24) associated with insulin and HOMA-B, respectively.Conclusion:PPM1K rs1440581 may affect changes in glucose metabolism during weight loss, and this effect is dependent on dietary fat and carbohydrate intakes. ...
In response to the high-fat diet, the T allele was associated with a higher reduction of insulin (β ± SE: -0.77 ± 0.40 μU/mL; P = 0.0 …
Tissue distribution of beta 3-adrenergic receptor mRNA in man.
Krief S, Lönnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P, Strosberg AD, Ricquier D, Emorine LJ. Krief S, et al. Among authors: Arner P. J Clin Invest. 1993 Jan;91(1):344-9. doi: 10.1172/JCI116191. J Clin Invest. 1993. PMID: 8380813 Free PMC article.
Expression of beta 1- and beta 2-receptor genes and correlation to lipolysis in human adipose tissue during childhood.
Marcus C, Bolme P, Karpe B, Brönnegård M, Selldén H, Arner P. Marcus C, et al. Among authors: Arner P. J Clin Endocrinol Metab. 1993 Apr;76(4):879-84. doi: 10.1210/jcem.76.4.8097202. J Clin Endocrinol Metab. 1993. PMID: 8097202
In infants and children less than 7 yr old, bar2 levels were twice as high (P < 0.01) as those in adults, and in infants 1-4 months old, bar2 mRNA levels were higher than bar1 levels (P < 0.01). ...The maximal lipolytic response to adrenaline was higher than that to noradrenaline in infants (P < 0.01), whereas the opposite was found in adults (P < 0.01). ...

In infants and children less than 7 yr old, bar2 levels were twice as high (P < 0.01) as those in adults, and in infants 1-4 month

Metabolic effects of liposuction--yes or no?
Arner P. Arner P. N Engl J Med. 2004 Sep 23;351(13):1354-7; author reply 1354-7. N Engl J Med. 2004. PMID: 15390364 No abstract available.
Adrenoceptor genes in human obesity.
Arner P, Hoffstedt J. Arner P, et al. J Intern Med. 1999 Jun;245(6):667-72. doi: 10.1046/j.1365-2796.1999.00495.x. J Intern Med. 1999. PMID: 10395196 Review.
554 results
Jump to page
Feedback